

W|A|M Global ASX: WGB

The world's most compelling undervalued growth companies.



Net Tangible Assets (NTA) per share before tax

June 2026

223.50c

May 2026

218.49c

The net current and deferred tax asset/(liability) position of the Company for June 2026 is 5.51 cents per share. This includes 0.29 cents per share of tax assets resulting from the acquisition of investment companies and 0.05 cents per share of income tax losses available to the Company in future periods.

Dividend highlights

13.2c

Annualised fully franked interim dividend (per share)

77.1c

Dividends paid since inception (per share)

110.1c

Dividends paid since inception, when including the value of franking credits (per share)

6.3%

Annualised fully franked interim dividend yield*

9.0%

Grossed-up dividend yield*

68.3c

Profits reserve (per share)

Assets

\$804.9m

Investment portfolio performance[^] (pa since inception June 2018)

8.2%

MSCI World Index (AUD): 13.4%

Month-end share price (at 30 June 2026)

\$2.11

^{*}Based on the 30 June 2026 share price and the annualised FY2026 fully franked interim dividend of 13.2 cents per share. Grossed-up dividend yield includes the value of franking credits and is based on a tax rate of 30%.

[^]Investment portfolio performance is before expenses, fees, taxes and the impact of capital management initiatives to compare to the relevant index which is before expenses, fees and taxes.

[Catriona Burns shares market insights from her recent US trip](#)

[Nick Healy in Capital Brief analysing SpaceX's recent IPO](#)

The WAM Global (ASX: WGB) investment portfolio increased in June. Semiconductor equipment manufacturer ASML Holding (AEX: ASML) and medical technology provider Edwards Lifesciences Corporation (NYSE: EW) were contributors to the investment portfolio performance.

ASML


ASML Holding (ASML) designs and manufactures lithography systems that are essential for the production of semiconductors. The company holds a monopoly position in extreme ultraviolet lithography, the most advanced iteration of this technology. ASML is a clear beneficiary of capital expenditure related to artificial intelligence (AI), which was exemplified by two developments during the month. First, leading US-based memory producer Micron Technology (NASDAQ: MU) delivered a strong quarterly result, which will support continued capacity expansion and, in turn, demand for ASML's lithography systems and services. Second, SpaceX's (NASDAQ: SPCX) successful IPO strengthened the funding outlook for its proposed 'Terafab' foundry, which could provide a further source of orders for ASML. Looking ahead, we anticipate robust earnings growth driven by the adoption of ASML's newest generation machinery, continued demand from core customers including Taiwan Semiconductor Manufacturing Company (TWSE: 2330), Intel (NASDAQ: INTC) and Samsung Electronics (KRX: 005930), and a growing installed base that generates high-margin recurring service revenue.




Edwards Lifesciences Corporation (Edwards) is the global leader in minimally invasive heart valves and structural heart treatments. Its core franchise, Transcatheter Aortic Valve Replacement (TAVR), accounted for over 70% of revenues in 2025. The shares outperformed in June after the US Centers for Medicare and Medicaid Services (CMS) published a proposal to expand the conditions under which it will reimburse TAVR procedures. The proposal extends coverage to asymptomatic patients and removes several administrative requirements that hospitals previously had to meet, streamlining procedure growth. The read-through for Edwards is particularly favourable, as its valve is currently the only device with FDA approval for use in asymptomatic patients. A final decision on the CMS proposal is expected by September 2026 and, if approved, this would broaden access to this important treatment, support better patient outcomes, and expand the total addressable market for Edwards' TAVR franchise. Given its largest competitors' relatively weak recent durability data, we expect Edwards to continue growing market share in TAVR over the coming quarters. We believe the strength of its core franchise, together with considerable growth in its earlier-stage tricuspid and mitral product lines, should drive further earnings growth and act as a catalyst for the stock.

Fully franked dividends since inception


Cents per share



Quality global companies by sector



Portfolio by geographical exposure




Top 20 holdings (alphabetical order)

Code	Company Name	Country of Domicile/listing*
2330 TT	Taiwan Semiconductor Manufacturing Company	Taiwan
AMRZ US	Amrize	United States
AMZN US	Amazon.com	United States
APH US	Amphenol Corporation	United States
ASML NA	ASML Holding	Netherlands
DY US	Dycom Industries	United States
ENR GR	Siemens Energy	Germany
EW US	Edwards Lifesciences Corporation	United States
FERG US	Ferguson Enterprises	United States
GOOG US	Alphabet	United States
ICE US	Intercontinental Exchange	United States
MSCI US	MSCI	United States
RBA US	RB Global	United States
SAF FP	Safran	France
SNPS US	Synopsys	United States
TEX US	Terex Corporation	United States
TMO US	Thermo Fisher Scientific	United States
TRU US	TransUnion	United States
TW US	Tradeweb Markets	United States
V US	Visa	United States

*Underlying business operations may comprise multiple geographies.

Our proven investment process



Catalyst: a major event that alters the market's perception of a company or its earnings momentum which will lead to a rerating of the investee company's share price.

About the Investment Manager

Wilson Asset Management has a track record of making a difference for shareholders and the community for over 28 years.

As the investment manager for nine leading listed investment companies (LICs) and four unlisted funds, Wilson Asset Management has a diversified offering of Australian and global listed equities and alternative assets.

Wilson Asset Management created and is the lead supporter of the first LICs to deliver both investment and social returns: Future Generation Australia (ASX: FGX) and Future Generation Global (ASX: FGG), as well as Future Generation Women.

\$6.0 billion	in funds under management
130,000	retail and wholesale investors
>250 years	combined investment experience
13	investment products

Listed Investment Companies

- W | A | M Capital
- W | A | M Leaders
- W | A | M Global
- W | A | M Microcap
- W | A | M Income Maximiser
- W | A | M Alternative Assets
- W | A | M Strategic Value
- W | A | M Research
- W | A | M Active

Key contacts

Geoff Wilson AO
Chairman & Chief Investment Officer
X (Twitter)
[@GeoffWilsonWAM](https://twitter.com/GeoffWilsonWAM)
(02) 9247 6755

Catriona Burns
Chief Executive Officer
0487 497 437

Joe Camilleri
Director of Finance
0402 759 790

Alexandra Hopper Irwin
Head of Corporate Affairs and Marketing
0431 381 295

For more information visit:
wilsonassetmanagement.com.au



Stay informed

Please subscribe to our [newsletter](#) and follow us on our social channels [X](#), [LinkedIn](#) and [Facebook](#) for real-time insights and market updates from our investment experts, along with the latest news, results and events.

Lonsec Disclaimer: The rating issued 04/2026 for WAM Global Limited is published by Lonsec Research Pty Limited ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit <https://www.lonsec.com.au/> for ratings information and to access the full report. © 2026 Lonsec. All rights reserved.

Independent Investment Research (IIR) Disclaimer: The rating ascribed by IIR is provided under the Annual LIC Research Participation Scheme whereby the LIC Manager provides information and IIR rating is monitored on a monthly basis to ensure its currency. The manager is a participant and as such this rating is current. Please note an ascribed rating does not constitute advice in any form. We recommend to any reader that no investment decisions are made on this fund without seeking advice from your Wealth Manager.

Zenith Disclaimer: The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (ASX: WGB assigned November 2025) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at [Fund Research Regulatory Guidelines](#).